EUVIMEDEUVIMED entdecken
Crossref

Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

Kumar Prabhash iD, Vanita Noronha iD, Akash Pawar iD, Ankush Shetake, Rajendra Badwe iD

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3175-3176

DOI: 10.1200/jco-26-01376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Kumar Prabhash und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kumar Prabhash, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, Department of Me…. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Kumar Prabhash, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaf…

ORCID-Profile: Kumar Prabhash, Vanita Noronha, Akash Pawar, Rajendra Badwe

Zitieren

APA

Prabhash, K., Noronha, V., Pawar, A., Shetake, A., & Badwe, R. (2026). Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology, 44(32), 3175-3176. https://doi.org/10.1200/jco-26-01376

Vancouver

Prabhash K, Noronha V, Pawar A, Shetake A, Badwe R. Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology. 2026;44(32):3175-3176. doi:10.1200/jco-26-01376

BibTeX
@article{Prabhash2026,
  author = {Prabhash, Kumar and Noronha, Vanita and Pawar, Akash and Shetake, Ankush and Badwe, Rajendra},
  title = {Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3175--3176},
  doi = {10.1200/jco-26-01376}
}
Kostenlos starten →